Watchlist

Watchlist
Aeglea BioTherapeutics, Inc. (AGLE)
Aeglea BioTherapeutics, Inc. (AGLE)
Aeglea Biotherapeutics (AGLE) Presents At BMO Capital Markets 2017 Prescriptions For Success Healthcare Conference - Slideshow
The following slide deck was published by Aeglea BioTherapeutics in conjunction with this Read more …
Your Daily Pharma Scoop: Gilead's Potential, Celgene CAR-T Candidate, Cellectar Soars
This abridged Daily Scoop is published by Avisol Capital Partners, which runs the physician-managed Total Pharma Tracker healthcare investment research service on Seeking Alpha Marketplace. Total Pharma Tracker subscribers get the full version with actionable ideas one day ea…
Midday Gainers / Losers
Gainers: AMWD +25% . FMI +22% . CGG +17% . AMPE +20% . AMBA +15% . AGLE +15% . CLRO +14% . XNET +13% . CASI +12% . MARA +12% . More news on: American Woodmark Corporation, Foundation Medicine, Inc., CGG, Stocks on the move, Read more …
Aeglea Biotherapeutics (AGLE) Presents At Society For Immunotherapy Of Cancer - Slideshow
The following slide deck was published by Aeglea BioTherapeutics in conjunction with this Read more …
Aeglea BioTherapeutics beats by $0.07, beats on revenue
Aeglea BioTherapeutics (NASDAQ: AGLE ): Q3 EPS of -$0.48 beats by $0.07 . More news on: Aeglea BioTherapeutics, Earnings news and commentary, Healthcare stocks news, , Read more …
Aeglea BioTherapeutics beats by $0.01, beats on revenue
Aeglea BioTherapeutics (NASDAQ: AGLE ): Q2 EPS of -$0.47 beats by $0.01 . More news on: Aeglea BioTherapeutics, Earnings news and commentary, Healthcare stocks news, , Read more …
Stocks to watch next week
Key events are scheduled for the companies listed below next week. More news on: Marriott International, Inc., CBS Corporation, Tyson Foods Inc., Consumer stocks news, Financial stocks news, Tech stocks news, Healthcare stocks news, Top Breaking stock news, Read more …
Aeglea Bio expects to expand early-stage study of lead product candidate AEB1102 into specific tumors types by Q4/Q1; shares down 8%
In an update to investors, Aeglea BioTherapeutics ( AGLE -7.7% ) reports that its Phase 1 clinical trial assessing the safety, tolerability and pharmacokinetics of lead product candidate AEB1102 has demonstrated clinical proof of mechanism. More news on: Aeglea BioTherapeutics, Healt…
Aeglea BioTherapeutics EPS in-line, misses on revenue
Aeglea BioTherapeutics (NASDAQ: AGLE ): Q1 EPS of -$0.47 in-line. More news on: Aeglea BioTherapeutics, Earnings news and commentary, Healthcare stocks news, , Read more …
Aeglea BioTherapeutics' (AGLE) CEO David Lowe on Q4 2016 Results - Earnings Call Transcript
Aeglea BioTherapeutics (AGLE) Q4 2016 Earnings Conference Call March 23, 2017 04:30 PM ET Executives Paul Arndt - MD, LifeSci Advisors, IR David Lowe - Co-Founder, President and CEO Charles York - CFO Analysts Chad Messer - Needham and Company Yanan Zhu - Wells Fargo Je…
Aeglea BioTherapeutics reports FY results
Aeglea BioTherapeutics (NASDAQ: AGLE ): FY EPS of -$2.22 Revenue of $4.63M (-23.8% Y/Y) Press Release More news on: Aeglea BioTherapeutics, Earnings news and commentary, Healthcare stocks news, ,
Aeglea BioTherapeutics, Inc. (AGLE)